---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-014227"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:43:57.215538+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Clene reports Q1 net loss of $11.8M, cash $18.4M; ALS data milestones expected mid-2023

## Summary
- Net loss $11.8M ($0.15/sh) vs $13.4M ($0.21/sh) in Q1 2022; R&D $7.4M, G&A $3.4M.
- Cash and marketable securities $18.4M as of Mar 31, expected to fund ops into Q3 2023.
- ALS survival benefit data from HEALEY and RESCUE-ALS trials presented at AAN; biomarker/long-term survival data expected mid-2023.
- Appointed Benjamin Greenberg, M.D., as Head of Medical; entered $25M equity facility with Lincoln Park.
- MS regulatory discussions anticipated in Q4 2023; advancing partnership opportunities.

## SEC filing metadata
- accession: 0001437749-23-014227
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/0001437749-23-014227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/clnn20230505_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-014227
- JSON: https://secwatch.observer/filing/0001437749-23-014227.json
- Plain text: https://secwatch.observer/filing/0001437749-23-014227.txt

## Key facts
- Earnings Releases
  Clene Inc. reported first quarter ended March 31, 2023 results: net income $11.8 million, EPS $0.15 per share.
  - Period: first quarter ended March 31, 2023
  - Net income: $11.8 million
  - EPS: $0.15 per share
  - Result: reported results
  source text: Clene reported a net loss of $11.8 million , or $0.15 per share, for the quarter ended March 31, 2023, compared to a net loss of $13.4 million , or $0.21 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774923014227/0001437749-23-014227-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.